Orchid Pharma Limited, a leading pharmaceutical company, experienced a 4.2% increase in its shares to ₹1,188.10 on Monday after announcing a partnership with Cipla Limited. The collaboration focuses on launching Cefepime-Enmetazobactam, a new drug to treat complex urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) throughout India.